Latest Posters

With this poster, dive into the world of mass spectrometry troubleshooting, and discover detailed tables listing the accurate mass of elements, organic solvents and potential contaminant ions.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise.

Designing and performing assays that accurately measure small molecule binding kinetics is an important part of the drug discovery process. It allows researchers to predict the efficacy of potential novel therapeutics and make quick decisions about weak binders.

This poster demonstrates how a novel, precise and highly controlled iPSC reprogramming technology overcomes these limitations and enables the generation of mature cell types and isogenic models of neurodegenerative disease.

Many promising drugs which show efficacy in animal models have failed in the clinic due to interspecies variance in nociception mechanisms. Hence, consistent, scalable human in vitro models are required to accelerate potential therapeutics to the clinic.

While animal models and primary cells remain valuable resources, neuronal drug development faces many challenges. Not least, the variability and inaccuracy of traditional model systems can result in the failure to translate data into successful clinical trials.

Drug discovery is a time-consuming, resource-intensive part of developing therapeutic targets. This is especially true for commonly considered 'undruggable' targets such as transmembrane proteins.

Traditionally, there has been a compromise between performance and sustainability.

The NovaSeq X Plus system enables sequencing of >20,000 genomes per year and delivers data in half the time with a 2.5x improvement in throughput. Breakthrough advancement in chemistry, optics and software contribute to fast, highly accurate and cost-effective data.

Researchers looking to answer complex biological questions often require increased statistical power, larger studies and deeper sequencing methods.